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Inflammatory cytokines in acute renal failure. A growing
body of evidence indicates that inflammatory mechanisms con-
tribute to toxin-induced acute renal failure as well as ischemia/
reperfusion injury. A role for tumor necrosis factor-a (TNF-
a) in mediating the inflammatory injury in cisplatin-induced
acute renal failure has recently been established. Cisplatin in-
duces the expression of TNF-a and TNF receptor subtype 2
(TNFR2) within the kidney. Genetic deletion of either TNF-a
or TNFR2 substantially reduces cisplatin-induced renal failure
and also necrosis and apoptosis within the kidney. Studies will
be required to determine if pharmacologic inhibition of TNF-a
might reduce cisplatin-induced renal failure in humans.
Acute renal failure (ARF) occurs in 5% to 7% of hos-
pitalized patients [1, 2] and results in a mortality rate of
about 50% [3]. A particularly disturbing feature has been
the inability since the mid-1960s to substantially lower
mortality rates in ARF [4, 5]. The high mortality of pa-
tients with ARF is not explained entirely by comorbid
conditions. Rather, ARF is an independent risk factor
for mortality, increasing the risk of death by 10- to 15-
fold compared to patients without ARF [6]. The financial
costs of acute renal failure are estimated to be 8 billion
dollars per year, or about $130,000 per life-year saved [5].
It is unlikely that this high mortality and associated cost
will be reduced until we have a better understanding of
the cellular and molecular mechanisms of cell injury and
recovery.
INFLAMMATION IN ACUTE RENAL FAILURE
Compelling evidence now exists that inflammation is a
major factor in ischemia/reperfusion injury in the kid-
ney [7]. Several laboratories have shown a prominent
peritubular neutrophil accumulation in both the cortex
and medulla after ischemia/reperfusion [8–11]. Leuko-
cytes localize to sites of injury as a result of the integrated
actions of adhesion molecules, cytokines, and chemotac-
tic factors [12]. Soluble mediators such as cytokines and
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chemokines are released from activated or injured kid-
ney cells, and attract and activate leukocytes to sites of
injury. The adherence of neutrophils to the vascular en-
dothelium is a first step in the extravasation of cells into
the interstitium. This process is mediated by selectins,
integrins, and endothelial adhesion molecules [e.g., in-
tercellular adhesion molecule-1 (ICAM-1) and vascular
cellular adhesion molecule-1 (VCAM-1)] [13, 14]. Inhi-
bition of ICAM-1 [14], or depletion of neutrophils [14]
or lymphocytes [15] ameliorates ischemic renal injury.
In humans, ARF often occurs in a setting of infection
and a systemic inflammatory response syndrome. Ele-
vations in both proinflammatory cytokines [e.g., tumor
necrosis factor-a (TNF-a), interleukin-1b (IL-1b), and
interleukin-6 (IL-6)], and anti-inflammatory cytokines
[e.g., interleukin-10 (IL-10)] have been demonstrated in
humans with ARF [16]. Moreover, the levels of certain
cytokines and gene polymorphisms for certain cytokines
may have predictive value in clinical acute renal failure
[16, 17]. Together, these data point to an important role
of leukocytes, adhesion molecules, and chemokines and
cytokines in the pathogenesis of acute renal injury.
INFLAMMATORY CYTOKINES IN CISPLATIN
NEPHROTOXICITY
In contrast to ischemia/reperfusion injury, there is rela-
tively little information concerning the role of inflamma-
tion in toxic ARF. Cisplatin is a highly effective treatment
of certain forms of cancer [18], but causes ARF in many
patients [19–21]. In bone marrow transplant recipients
who received cisplatin, severe renal dysfunction devel-
oped in 21% and increased the mortality rate 5-fold [22].
In an animal model of cisplatin nephrotoxicity, Kelly et
al reported that blocking ICAM-1 reduced the severity
of cisplatin-induced renal injury [23], similar to what had
been seen in ischemic injury. Deng et al [11] demonstrated
an up-regulation of TNF-a and ICAM-1 expression
in the kidney in response to cisplatin. The expression of
these molecules, the influx of neutrophils, as well as the
extent of cisplatin nephrotoxicity, were diminished by in-
fusion of IL-10, an anti-inflammatory cytokine that sup-
presses the activation of leukocytes and the production of
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Fig. 1. Effects of cisplatin and tumor necrosis factor-a (TNF-a) in-
hibitors on cytokine gene expression. Cytokine gene expression in kid-
ney was measured 72 hours after injection of cisplatin (solid bars), or
cisplatin and either GM6001 (open bars) or pentoxifyline (shaded bars).
Gene expression levels are expressed relative to levels in saline-treated
mice. From reference [25].
proinflammatory cytokines and chemokines [24]. These
studies prompted us to examine the mediators of inflam-
mation in cisplatin-induced renal injury.
Cisplatin nephrotoxicity was induced by a single injec-
tion of cisplatin in mice. Kidneys were harvested at var-
ious intervals after injection of cisplatin and the mRNA
levels for a total of 32 cytokines and chemokines were
measured at each time point [25]. We found significant
increases in mRNA levels for TNF-a, Regulated on Ac-
tivation, Normal T Expressed and Secreted (RANTES),
macrophage inflammatory protein-2 (MIP-2), monocyte
chemoattractant protein-1 (MCP-1), IL-1b , osteopontin,
ICAM-1, and TGF-b in kidneys from cisplatin-treated
mice (Fig. 1). Moreover, these increases were prevented
by treatment of animals with inhibitors of TNF-a, sug-
gesting that TNF-a was driving the expression of these
other inflammatory mediators.
To address the role of TNF-a in the pathogenesis of
cisplatin-induced ARF, renal function and renal histol-
ogy were examined in animals treated with cisplatin in the
presence or absence of TNF-a inhibitors, and also in TNF-
a knockout mice [25]. Treatment with either of two TNF-
a inhibitors, GM6001 and a TNF-neutralizing antibody,
reduced cisplatin-induced renal dysfunction (Fig. 2),
and also reduced histologic evidence of injury. TNF
knockout mice also sustained less renal injury than wild-
type mice [25], and had markedly higher survival rates
following cisplatin injection (Fig. 3). These results, which
have been confirmed by Tsuruya et al [26], establish an
important role for TNF-a in the pathogenesis of cisplatin
nephrotoxicity. TNF-a appears to play a role in renal is-
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Fig. 2. Effect of tumor necrosis factor-a (TNF-a inhibitors on cisplatin
nephrotoxicity. Mice were injected with saline (), 20 mg/kg cisplatin
(•), or cisplatin and GM6001 () or neutralizing TNF-a antibody ().
Blood urea nitrogen was measured at the indicated times. ∗P < 0.01 vs.
cisplatin. From reference [25].
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Fig. 3. Survival of wild-type (WT) and tumor necrosis factor knockout
(TNF KO) mice after cisplatin injection (15 mg/kg).
chemic injury [27–29] and myoglobinuric renal failure, as
well [30].
TNFR2 MEDIATES TNF-a ACTIONS IN
CISPLATIN TOXICITY
The biologic activities of TNF-a are mediated by two
functionally distinct receptors, TNFR1 (p55) and TNFR2
(p75). Many of the cytotoxic and proinflammatory ac-
tions of TNF-a are mediated by TNFR1 [31, 32]. TNFR1-
deficient mice are resistant to endotoxic shock and show
abrogated induction of adhesion molecules by TNF-a
[33, 34]. In contrast, TNFR2-deficient mice exhibit only
subtle defects [35], and its role in disease is unclear
[36, 37]. TNFR2 is thought to cooperate with TNFR1
by passing ligands to TNFR1 [38], or forming hetero-
complexes with TNFR1 [39]. However, the engagement
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Fig. 4. Role of tumor necrosis factor receptor 1 (TNFR1) and tumor
necrosis factor receptor 2 (TNFR2) in cisplatin nephrotoxicity. Mice
from each strain were injected with saline or cisplatin (CP). Blood urea
nitrogen was measured at the indicated times after injection as a mea-
sure of renal function. Cisplatin caused marked elevations of urea in
the C57BL/6- and TNFR1-deficient mice. TNFR2-deficient mice had
significantly lower urea levels. ∗P < 0.015 vs. C57BL/6. From reference
[51].
of TNFR2 by TNF-a also leads to TNFR1-independent
cellular events, including apoptosis of activated T-cells
[40, 41], thymocyte proliferation [42], and inhibition of
early hematopoiesis [43]. We used TNFR1-, TNFR2-, and
TNF-a–deficient mice to examine the TNF-a receptor
subtype that mediates cisplatin-induced renal injury and
the regulation of their expression in response to cisplatin.
Wild-type and TNFR1-deficient mice developed se-
vere renal failure following injection with cisplatin
(Fig. 4). In contrast, TNFR2-deficient mice had better
preservation of function. The histologic findings also re-
vealed less severe damage in the TNFR2-deficient mice.
Cisplatin treatment of wild-type and TNFR1-deficient
mice resulted in severe tubular injury reflected by cast
formation, loss of brush border membranes, sloughing of
tubular epithelial cells, and dilation of tubules through-
out the cortex and outer medulla. These changes were
minimal in kidneys from TNFR2-deficient mice treated
with cisplatin. Thus, the nephrotoxic effects of cisplatin,
at least those mediated by TNF-a, are signaled through
TNFR2 rather than TNFR1. TNFR2 has been shown to
play an important role in several other disease models.
For example, TNFR2 is up-regulated in intestinal inflam-
mation, and TNFR2-deficient mice develop less severe
intestinal inflammation [44]. TNFR2 also participates in
intestinal graft versus host disease [45] and accelerates
the early phase of collagen-induced arthritis [46]. The re-
cent report by Akassoglou et al [47] demonstrated that
over-expression of TNFR2, in the absence of TNFR1
and even TNF-a, induces vascular inflammation and is-
chemic necrosis in the central nervous system. In a model
of obstructive uropathy, Guo et al [48] found that both
TNFR1 and TNFR2 contributed to interstitial fibrosis,
nuclear factor jB (NFjB) activation, and TNF-a ex-
pression. On the other hand, Cunningham et al [49] de-
termined that endotoxin-induced acute renal injury was
dependent upon intrarenal TNFR1, consistent with the
known role of TNFR1 in mediating endotoxic shock [33].
The expression of TNFR1 and TNFR2, which has
NFjB and other transcription factor binding sites in its
promoter [50], can be altered in disease states. Cisplatin
increased the expression of TNFR1 about 3-fold, and
increased TNFR2 expression 6- to 9-fold over saline-
treated controls. To examine whether the up-regulation
of either TNFR1 or TNFR2 is dependent upon TNF-
a, receptor mRNA was measured in cisplatin-treated
TNF-a–deficient mice. The expression of TNFR1 was
similar in wild-type and TNF-a–deficient mice treated
with cisplatin [51]. However, the up-regulation of TNFR2
mRNA was blunted in TNF-a–deficient mice. Likewise,
kidney TNFR2 protein levels were increased by cisplatin,
and this increase was blunted in TNF-a–deficient mice.
These results are consistent with ligand-dependent up-
regulation of TNFR2 in cisplatin nephrotoxicity. This up-
regulation may serve to sensitize the kidney to the effects
of TNF-a.
INHIBITION OF TNF-a PRODUCTION LIMITS
CISPLATIN TOXICITY
Drugs that target TNF-a production or action may pro-
tect against cisplatin nephrotoxicity. In this regard, Li
et al [52] reported that salicylates reduced cisplatin
nephrotoxicity in rats. High doses of salicylates are
thought to inhibit NFjB and its upstream activator IjB
kinase b [53, 54], as opposed to working through cy-
clooxygenase, the classic target of nonsteroidal anti-
inflammatory drugs. Activation of NFjB can increase the
production of various inflammatory cytokines, including
TNF-a [55]. Therefore, we performed experiments to de-
termine if salicylates reduce cisplatin-induced renal dys-
function by inhibiting the production of TNF-a. First,
we confirmed in mice that salicylates reduce cisplatin
nephrotoxicity. Administration of salicylate together with
cisplatin significantly reduced both the blood urea nitro-
gen (210 ± 14 vs. 98 ± 25 mg/dL, P < 0.005) and crea-
tinine (3.6 ± 0.4 vs. 1.0 ± 0.3 mg/dL, P = 0.0005) levels
compared with cisplatin alone [56]. The improvement in
renal function was accompanied by less severe histologic
damage. Consistent with previous reports [57, 58], cis-
platin produced a large increase in both necrosis and
apoptosis. Both forms of cell death were significantly
reduced by salicylate (Fig. 5). Treatment with salicylate
also inhibited the up-regulation of TNF-a by cisplatin.
Next, we determined that the protective effects of salicy-
lates were mediated via inhibition of TNF-a. Wild-type
mice or TNF-a–deficient mice received cisplatin in the
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Fig. 5. Effect of salicylate and cisplatin on tubular necrosis and apop-
tosis. Tubular necrosis (solid bars) and apoptosis (hatched bars) were
scored in kidneys from mice treated with saline, salicylate, cisplatin, or
cisplatin and salicylate. +P < 0.001 vs. saline, ∗P < 0.001 vs. cisplatin.
From reference [56].
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Fig. 6. Tumor necrosis factor-a (TNF-a) dependence of salicylate ac-
tions in cisplatin nephrotoxicity. B6129SF/J- or TNFa-deficient mice
were treated with either cisplatin or cisplatin and salicylate. Blood urea
nitrogen (solid bars) or serum creatinine (hatched bars) was measured
72 hours after injection. +P < 0.05 vs. cisplatin. ++P < 0.01 vs. cisplatin
B6129SF/J. From reference [56].
presence or absence of sodium salicylate. As shown in
Figure 6, wild-type mice developed severe renal failure,
and this was significantly reduced by salicylate. As noted
earlier, TNF-a–deficient mice developed less renal dys-
function when compared to the wild-type mice. Of note,
salicylate had no additional benefit in the absence of en-
dogenous TNF-a.
The reduction of TNF-a production by salicylates may
have been mediated by reducing IjB degradation. Thus,
cisplatin increased the degradation of IjB in cultured
mouse renal proximal tubule cells in a time-dependent
manner. However, in the presence of salicylate this degra-
dation of IjB was inhibited. Degradation of IjB al-
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Fig. 7. Effect of cisplatin and salicylate on tumor necrosis factor (TNF-
a) expression in renal proximal tubule cells. Proximal tubule cells were
treated for 12 hours with the indicated additions. TNF-a mRNA was de-
termined by real time reverse transcription-polymerase chain reaction
(RT-PCR). +P < 0.05 vs. cisplatin. From reference [56].
lows the nuclear localization of NFjB and subsequent
transcriptional activation of target genes [59], including
TNF-a [55]. Gel shift assays indicated that treatment of
proximal tubule cells with cisplatin increased the bind-
ing of nuclear extracts to a consensus NFjB-binding
sequence. Treatment with salicylate prevented the
cisplatin-induced increase in NFjB binding. Treatment
of proximal tubule cells with cisplatin increased TNF-a
mRNA in proximal tubule cells 9-fold at 12 hours, while
salicylate treatment inhibited the cisplatin-induced TNF-
a mRNA expression significantly, and also reduced basal
TNF-a expression (Fig. 7). Together, these observations
suggest that salicylates may reduce TNF-a transcription
by stabilizing IjB and preventing NFjB from binding
to the TNF-a promoter [55]. Kim et al [60] examined
the effects of another TNF-a inhibitor, pentoxifyline, on
cisplatin nephrotoxicity in rabbits. They found that pre-
treatment with pentoxifyline reduced cisplatin-induced
renal TNF-a mRNA expression, and also reduced renal
dysfunction and histologic evidence of necrosis and apop-
tosis. Thus, strategies which result in blockade of TNF-a
production and/or action may be effective in reducing cis-
platin induced acute renal injury. One concern regarding
the use of anti-TNF-a agents to prevent nephrotoxicity in
humans is the possibility that TNF-a may mediate some
of the antitumor actions of cisplatin. In this case, inhi-
bition of TNF-a might reduce the antitumor efficacy of
cisplatin, in addition to reducing its nephrotoxicity. Al-
though Li et al [52] did not find any effect of salicylate
on tumor killing by cisplatin, this issue deserves further
study.
It should be noted that cisplatin clearly has toxic ef-
fects on renal epithelial cells that are not mediated via
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TNF-a. Thus, deletion or inhibition of TNF-a provided
only partial protection against cisplatin nephrotoxicity in
vivo (Figs. 2 and 4). The mechanisms of direct toxicity
of cisplatin to renal epithelial cells have been examined
extensively in vitro and include DNA damage [61], lipid
peroxidation, mitochondrial dysfunction [62], and activa-
tion of caspases [63] and protein kinases [64].
CONCLUSION
Studies from our laboratory [25, 51, 56] and others [11,
26, 60, 65], point to the important role of proinflammatory
cytokines, TNF-a in particular, in the pathogenesis of cis-
platin nephrotoxicity. Additional studies are required to
define the mechanisms of TNF-a production in response
to cisplatin and the mechanisms whereby TNF-a pro-
duces renal injury. Answers to these questions may also
be relevant to other forms of acute renal injury. Finally,
it remains to be determined if antagonism of TNF-a pro-
duction or action may have therapeutic benefit in acute
renal failure.
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